JP7590341B2 - ミトコンドリアを含むエアロゾル化組成物及びその使用方法 - Google Patents

ミトコンドリアを含むエアロゾル化組成物及びその使用方法 Download PDF

Info

Publication number
JP7590341B2
JP7590341B2 JP2021560961A JP2021560961A JP7590341B2 JP 7590341 B2 JP7590341 B2 JP 7590341B2 JP 2021560961 A JP2021560961 A JP 2021560961A JP 2021560961 A JP2021560961 A JP 2021560961A JP 7590341 B2 JP7590341 B2 JP 7590341B2
Authority
JP
Japan
Prior art keywords
mitochondria
aerosolized composition
composition
mitochondrial
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529262A (ja
JPWO2020214644A5 (https=
JP2022529262A5 (https=
Inventor
ディー． マッカリー、ジェイムズ
ニド、ペドロ ジェイ． デル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2022529262A publication Critical patent/JP2022529262A/ja
Publication of JPWO2020214644A5 publication Critical patent/JPWO2020214644A5/ja
Publication of JP2022529262A5 publication Critical patent/JP2022529262A5/ja
Application granted granted Critical
Publication of JP7590341B2 publication Critical patent/JP7590341B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0883—Clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agents, e.g. microbubbles introduced into the bloodstream

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
JP2021560961A 2019-04-15 2020-04-15 ミトコンドリアを含むエアロゾル化組成物及びその使用方法 Active JP7590341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962834020P 2019-04-15 2019-04-15
US62/834,020 2019-04-15
PCT/US2020/028219 WO2020214644A1 (en) 2019-04-15 2020-04-15 Aerosolized compositions comprising mitochondria and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022529262A JP2022529262A (ja) 2022-06-20
JPWO2020214644A5 JPWO2020214644A5 (https=) 2023-04-25
JP2022529262A5 JP2022529262A5 (https=) 2023-04-25
JP7590341B2 true JP7590341B2 (ja) 2024-11-26

Family

ID=72837565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560961A Active JP7590341B2 (ja) 2019-04-15 2020-04-15 ミトコンドリアを含むエアロゾル化組成物及びその使用方法

Country Status (6)

Country Link
US (1) US20220395531A1 (https=)
EP (2) EP3955902B1 (https=)
JP (1) JP7590341B2 (https=)
CN (1) CN113905724A (https=)
ES (1) ES2988040T3 (https=)
WO (1) WO2020214644A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIA
KR102665782B1 (ko) * 2022-03-29 2024-05-14 주식회사 파이안바이오테크놀로지 동결 및 동결건조된 미토콘드리아 및 이의 용도
CA3257638A1 (en) * 2022-06-10 2023-12-14 Cellvie Ag COMPOSITION AND CRYOCONSERVATION PROCESS OF MITOCHONDRIA
CN115634178A (zh) * 2022-10-13 2023-01-24 广州华茜药业科技有限公司 补充机体细胞能量的线粒体组合物及其制备方法
CN115624515A (zh) * 2022-10-13 2023-01-20 广州华茜药业科技有限公司 一种抗皱抗衰的线粒体组合物及其应用
WO2025184537A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507729A (ja) 2016-01-15 2019-03-22 ザ チルドレンズ メディカル センター コーポレーション ミトコンドリアおよび組み合わされたミトコンドリア剤の治療的使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
DE3151275C2 (de) 1981-12-24 1986-07-10 SKF GmbH, 8720 Schweinfurt Befestigungsvorrichtung für Werkzeuge
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO2000041949A1 (en) 1999-01-18 2000-07-20 Earth Chemical Co., Ltd. Aerosol injection device
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US8616195B2 (en) * 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
CA2560415A1 (en) 2004-03-29 2005-10-13 The Procter & Gamble Company Aerosol
US7431222B2 (en) 2005-06-03 2008-10-07 Monterrosa Christopher H Aerosol spray masking device
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
EP2654865B1 (en) * 2010-12-22 2015-02-25 Koninklijke Philips N.V. Nebulizer device
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
US20160113887A1 (en) * 2014-06-05 2016-04-28 The Regents Of The University Of California Halogenated ether compounds and methods of inducing anesthesia
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
CN112243372A (zh) * 2018-05-31 2021-01-19 克里蒂泰克公司 从受试者分离肿瘤特异性免疫细胞用于过继性细胞疗法的方法和癌症疫苗
JP2022500059A (ja) * 2018-09-17 2022-01-04 エラスムス ユニバーシティ メディカルセンター ロッテルダムErasmus University Medical Center Rotterdam アデノソーム
JP2022542495A (ja) * 2019-07-24 2022-10-03 ルカ・サイエンス株式会社 細胞からミトコンドリアを得る方法および得られたミトコンドリア

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507729A (ja) 2016-01-15 2019-03-22 ザ チルドレンズ メディカル センター コーポレーション ミトコンドリアおよび組み合わされたミトコンドリア剤の治療的使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Aerosolised Mesenchymal Stem Cells Expressing Angiopoietin-1 Enhances Airway Repair，Stem Cell Rev and Rep，2018年09月03日，15，pp.112-125，10.1007/s12015-018-9844-7
Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits，European Respiratory Journal，2013年，vol.42, suppl.57，226
Mitochondrial Transplantation Attenuates Airway Hyperresponsiveness by Inhibition of Cholinergic Hyperactivity，Theranostics，2016年，vol.6, no.8，pp.1244-1260，10.7150/thno.13804
特集にあたって 医療分野におけるエアロゾルの応用ー吸入製剤の最新動向ー，J.Aerosol Res.，2006年，21(1)，p.4

Also Published As

Publication number Publication date
EP4461369A3 (en) 2025-02-12
CN113905724A (zh) 2022-01-07
EP4461369A2 (en) 2024-11-13
EP3955902A1 (en) 2022-02-23
US20220395531A1 (en) 2022-12-15
EP4461369C0 (en) 2026-02-25
EP3955902A4 (en) 2023-03-22
ES2988040T3 (es) 2024-11-19
JP2022529262A (ja) 2022-06-20
WO2020214644A1 (en) 2020-10-22
EP4461369B1 (en) 2026-02-25
EP3955902B1 (en) 2024-07-17
EP3955902C0 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP7590341B2 (ja) ミトコンドリアを含むエアロゾル化組成物及びその使用方法
US8586527B2 (en) Cerivastatin to treat pulmonary disorders
JP2023018100A (ja) ミトコンドリアおよび組み合わされたミトコンドリア剤の治療的使用
Hajos et al. Inhalable liposomal formulation for vasoactive intestinal peptide
US20250099377A1 (en) Method for pulmonary foam delivery
JP2026048627A (ja) 心不全の治療
KR20030053507A (ko) 동적-팽창 작용을 하는 폐계면활성제 조성물
CN114404450A (zh) 一种温敏型干细胞外泌体即型凝胶
Osman et al. Inhalable DNase I microparticles engineered with biologically active excipients
WO2004100972A1 (ja) 組織破壊を伴う疾患の予防及び／または治療剤
Mentkowski et al. Surface engineering enhances the therapeutic potential of systemically delivered extracellular vesicles following acute myocardial infarction
CN107998406A (zh) 一种级联靶向药物递送系统及其制备方法与应用
CN110384681A (zh) 一种用于肺纤维化的纳米制剂及其制备方法
JP2022120034A (ja) 吸入粉末剤、その評価方法及びその用途
Patel et al. Nanoliposomal dry powder formulations
HK40119609A (en) Aerosolized compositions comprising mitochondria and methods of use thereof
HK40068623A (en) Aerosolized compositions comprising mitochondria and methods of use thereof
HK40068623B (en) Aerosolized compositions comprising mitochondria and methods of use thereof
US20120034202A1 (en) Ameliorating agent for chronic obstructive pulmonary disease
US20230129137A1 (en) Use of tt-10-loaded nanoparticles for cardiac repair
CN121226499A (zh) 一种多肽及其作为基因递送载体的应用
Tao et al. Spatiotemporally controlled systemic delivery reshapes the in vivo fate of a cationic antimicrobial peptide for lung-selective exposure and an improved therapeutic index
CN120305204A (zh) 一种用于超声增强心脏药物递送的微泡-磷酸钙复合制剂的制备方法及其应用
Tanzi et al. Mesenchymal Stem Cells–Derived Extracellular Vesicles in Therapeutic Applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241114

R150 Certificate of patent or registration of utility model

Ref document number: 7590341

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150